One of the most important questions in obesity medicine is whether losing weight with newer medications translates into better long-term cardiovascular health. An August 2026 analysis of three-year SURMOUNT-1 data provides encouraging evidence for tirzepatide – but the distinction between predicted risk and actual cardiovascular events is essential. What researchers studied SURMOUNT-1 was a randomized
